Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study

INTRODUCTION: There is scant real-world information on switching treatment for anemia associated with chronic kidney disease (CKD) from methoxy polyethylene glycol-epoetin beta (PEG-Epo) to darbepoetin alfa (DA). TRANSFORM was a multi-center, observational study designed to describe the time course...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Adv Ther
Autors principals: Donck, Jan, Gonzalez-Tabares, Lourdes, Chanliau, Jacques, Martin, Heike, Stamatelou, Kyriaki, Manamley, Nick, Farouk, Mourad, Addison, Janet
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2014
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4245491/
https://ncbi.nlm.nih.gov/pubmed/25367412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-014-0161-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars